Literature DB >> 17440056

Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species.

Jérôme Alexandre1, Yumin Hu, Weiqin Lu, Helene Pelicano, Peng Huang.   

Abstract

Generation of reactive oxygen species (ROS) has been observed in cancer cells treated with paclitaxel, but the underlying mechanisms and therapeutic implications remain unclear. In the present study, we showed that paclitaxel promoted ROS generation through enhancing the activity of NADPH oxidase (NOX) associated with plasma membranes. Treatment of breast cancer cells caused an increased translocation of Rac1, a positive regulatory protein of NOX, to the membrane fraction. The paclitaxel-induced ROS generation occurred rapidly within several hours of drug exposure, with O(2)(-) and H(2)O(2) accumulation mainly outside the cells while the intracellular ROS remained unchanged. Importantly, the increase in extracellular ROS caused lethal damage to the bystander cancer cells not exposed to paclitaxel, as shown by two different methods using coculture systems where the bystander cells were differentiated from the paclitaxel-treated cells by fluorescent or radioactive labeling. This cytotoxic bystander effect was also observed with other microtubule-targeted agents vincristine and taxotere but not with 5-fluorouracil or doxorubicin. This toxic bystander effect was enhanced by CuZnSOD that converts O(2)(-) to H(2)O(2) and was abolished by a catalase that eliminates H(2)O(2). Furthermore, paclitaxel was able to induce an almost complete inhibition of proliferation of the bystander cells in the coculture system. Our study revealed a novel mechanism by which paclitaxel induces toxic bystander effect through generation of extracellular H(2)O(2) from the membrane-associated NOX. This may contribute to the potent anticancer activity of paclitaxel and provide a novel basis to improve the clinical use of this important drug.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17440056     DOI: 10.1158/0008-5472.CAN-06-3914

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  124 in total

1.  Stressed tumor cell, chemosensitized cancer.

Authors:  Erik A C Wiemer
Journal:  Nat Med       Date:  2011-12-06       Impact factor: 53.440

Review 2.  NRF2 and the Hallmarks of Cancer.

Authors:  Montserrat Rojo de la Vega; Eli Chapman; Donna D Zhang
Journal:  Cancer Cell       Date:  2018-05-03       Impact factor: 31.743

Review 3.  Radiation-induced bystander signalling in cancer therapy.

Authors:  Kevin M Prise; Joe M O'Sullivan
Journal:  Nat Rev Cancer       Date:  2009-04-20       Impact factor: 60.716

Review 4.  Cellular redox pathways as a therapeutic target in the treatment of cancer.

Authors:  Alberto J Montero; Jacek Jassem
Journal:  Drugs       Date:  2011-07-30       Impact factor: 9.546

5.  Engineering erythrocytes as a novel carrier for the targeted delivery of the anticancer drug paclitaxel.

Authors:  Gamaleldin I Harisa; Mohamed F Ibrahim; Fars Alanazi; Gamal A Shazly
Journal:  Saudi Pharm J       Date:  2013-01-07       Impact factor: 4.330

Review 6.  Reactive oxygen species: key regulators in vascular health and diseases.

Authors:  Qishan Chen; Qiwen Wang; Jianhua Zhu; Qingzhong Xiao; Li Zhang
Journal:  Br J Pharmacol       Date:  2017-07-11       Impact factor: 8.739

7.  Chemotherapeutic drug-specific alteration of microvascular blood flow in murine breast cancer as measured by diffuse correlation spectroscopy.

Authors:  Gabriel Ramirez; Ashley R Proctor; Ki Won Jung; Tong Tong Wu; Songfeng Han; Russell R Adams; Jingxuan Ren; Daniel K Byun; Kelley S Madden; Edward B Brown; Thomas H Foster; Parisa Farzam; Turgut Durduran; Regine Choe
Journal:  Biomed Opt Express       Date:  2016-08-24       Impact factor: 3.732

8.  Cell death induced by novel fluorinated taxanes in drug-sensitive and drug-resistant cancer cells.

Authors:  Jana Vobořilová; Vlasta Němcová-Fürstová; Jitka Neubauerová; Iwao Ojima; Ilaria Zanardi; Ivan Gut; Jan Kovář
Journal:  Invest New Drugs       Date:  2009-12-16       Impact factor: 3.850

9.  Paclitaxel combined with inhibitors of glucose and hydroperoxide metabolism enhances breast cancer cell killing via H2O2-mediated oxidative stress.

Authors:  Tanja Hadzic; Nükhet Aykin-Burns; Yueming Zhu; Mitchell C Coleman; Katie Leick; Geraldine M Jacobson; Douglas R Spitz
Journal:  Free Radic Biol Med       Date:  2010-01-18       Impact factor: 7.376

10.  Oxidative stress in NSC-741909-induced apoptosis of cancer cells.

Authors:  Xiaoli Wei; Wei Guo; Shuhong Wu; Li Wang; Peng Huang; Jinsong Liu; Bingliang Fang
Journal:  J Transl Med       Date:  2010-04-16       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.